Funder
Samsung Bioepis Co., Ltd.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Novartis Europharm Limited. Lucentis (ranibizumab). EPAR—product Information. Dublin, Ireland: Novartis Europharm Limited; 2018. https://www.ema.europa.eu/en/documents/product-information/lucentis-epar-product-information_en.pdf. Accessed 9 Sep 2022.
2. Genentech, Inc. Lucentis (ranibizumab injection) for intravitreal injection. Prescribing information. San Francisco, CA: Genentech, Inc.; 2018. https://www.gene.com/download/pdf/lucentis_prescribing.pdf. Accessed 9 Sep 2022.
3. Apte RS. Age-related macular degeneration. N Engl J Med. 2021;385:539–47. https://doi.org/10.1056/NEJMcp2102061.
4. Sene A, Chin-YeeD, Apte RS. Seeing through VEGF: innate and adaptive immunity in pathologic angiogenesis in the eye. Trends Mol Med. 2015;21:43–51. https://doi.org/10.1016/j.molmed.2014.10.005.
5. Pen JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331–71. https://doi.org/10.1016/j.preteyeres.2008.05.001.